FAU regulates carboplatin resistance in ovarian cancer

Genes Chromosomes and Cancer

Volumn 49, Issue 1, 2010, Pages 70-77

  Moss, Esther L ^a   Mourtada Maarabouni, Mirna ^a   Pickard, Mark R ^a   Redman, Charles W ^b   Williams, Gwyn T ^a  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PLASMID DNA; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; FAU GENE; GENE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULAR CLONING; OVARY CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; CARBOPLATIN; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE SILENCING; HUMANS; OVARIAN NEOPLASMS; RIBOSOMAL PROTEINS; RNA, SMALL INTERFERING;

MURINE SARCOMA VIRUS;

EID: 74949127389     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20721     Document Type: Article

References (32)

1. Abba MC, Drake JA, Hawkins KA, Hu Y, Sun H, Notcovich C, Gaddis S, Sahin A, Baggerly K, Aldaz CM. 2004. Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res 6:R499-R513.
2. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, EmmertBuck MR, Debelenko LV, Zhuang ZP, Lubensky IA, Liotta, Crabtree JS, Wang YP, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong QH, Spiegel AM, Burns AL, Marx SJ. 1997. Positional cloning of the gene for muliple endocrine neoplasia-type 1. Science 276:404-407.
3. Dent J, Hall GD, Wilkinson N, Perren TJ, Richmond I, Markham AF, Murphy H, Bell SM. 2003. Cytogenetic alterations in ovarian clear cellcarcinoma detected by comparative genomic hybridisation. Br J Cancer 88:1578-1583.
4. Gray D, Jubb AM, Hogue D, Dowd P, Kljavin N, Yi S, Bai W, Frantz G, Zhang Z, Koeppen H, Sauvage FJ, Davis D. 2005. Maternal embryonic leucine zipper kinas/murine protein serinethreonine kinase 38 is a promising target for multiple cancer. Cancer Res 65:9751-9761.
5. Guo B, Godzik A, Reed JC. 2001. Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J Biol Chem 276:2780-2785.
6. Kas K, Schoenmakers E, van de Ven W, Weber G, Nordenskjold M, Michiels L, Merregeart J, Larsson C. 1993. Assignment of the human FAU gene to a subregion of chromosome 11q13. Genomics 17:387-392.
7. Kibel AS, Huagen J, Guo C, Isaacs WB, Yan Y, Pienta KJ, Good-fellow PJ. 2004. Expression mapping at 12p 12-13 in advanced prostate carcinoma. Int J Cancer 109:668-672.
8. Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Cheng X, Okada M, Oishi T, Terakawa N. 1998. Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer. Cancer 82:697-702.
9. Lin ML, Park JH, Nishidate T, Nakamura Y, Katagiri T. 2007. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. Br Cancer Res 9:R17.
10. Marie SK, Okamoto OK, Uno M, Hasegawa APG, Oba-Shinjo SM, Cohen T, Camargo AA, Kosoy A, Carlotti CG, Toledo S, Moreira-Filho CA, Zago MA, Simpson AJ, Caballero OL. 2008. Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer 122:807-815.
11. Michiels L, Van der Rauwelaert E, Van Hasselt F, Kas K, Merregaert J. 1993. fau cDNA encodes a ubiquitin-like-S30 fusion protein and is expressed as an antisense sequence in Finkel-Biskis-Reilly murine sarcoma virus. Oncogene 8:2537-2546.
12. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly KF, Parkin DE, Haites NE. 1993. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 53:2128-2132.
13. Mourtada-Maarabouni M, Kirkham L, Farzaneh F, Williams GT. 2004. Regulation of apoptosis by FAU revealed by functional expression cloning and antisense expression. Oncogene 23:9419-9426.
14. Nakamura M, Tanigawa Y. 2003. Characterization of ubiquitin-like polypeptide acceptor protein, a novel pro-apoptotic member of the Bcl2 family. Eur J Biochem 270:4052-4058.
15. Nakayama K, Kanzaki A, Terada K, Mutoh M, Oqawa K, Suqiyama T, Takenoshita S, Itoh K, Yaeqashi N, Miyazaki K, Neamati N, Takebayashi Y. 2004. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin Cancer Res 10:2804-2811.
16. Okada S, Tsuda H, Takarabe T, Yoshikawa H, Taketani Y, Hirohashi S. 2002. Allelotype analysis of common epithelial ovarian cancers with special reference to comparison between clear cell adenocarcinoma with other histological types. Jpn J Cancer Res 93:798-806.
17. Penson R, Oliva E, Skates SJ, Glyptis T, Fuller AF, Jr, Goodman A, Seiden MV. 2004. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: A study in serial samples. Gynecol Oncol 93:98-106.
18. Pickard MR, Green AR, Ellis IO, Caldas C, Hedge VL, Mourtada-Maarabouni M, Williams GT. 2009. Dysregulation expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res 11:R60.
19. Richardson A, Kaye SB. 2008. Pharamacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy. Curr Mol Pharmacol 1:244-254.
20. Rossman TG, Wang Z. 1999. Expression cloning for arsenite-resistance resulted in isolation of tumor-suppressor fau cDNA: Possible involvement of the ubiquitin system in arsenic carcinogenesis. Carcinogenesis 20:311-316.
21. Sankaranarayanan R, Ferlay J. 2006. Worldwide burden of gynaecological cancer: The size of the problem. Best Pract Res Clin Obstet Gynaecol 20:207-225.
22. Schrami P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T, King W, Wilber K, Mihatsch MJ, Moch H. 2003. Combined array comparative genomic hybridization and tissue microarray suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 163:985-992.
23. Seraj MJ, Samant RS, Verderame MF, Welch DR. 2000. Functional evidence for a novel human breast carcinoma metastasis suppressor, MRMS1, encoded at chromosome 11q13. Cancer Res 60:2764-2769.
24. Shih IeM, Kurman RJ. 2004. A proposed model based on morphological and molecular genetic analysis. Am J Pathol 164: 1511-1518.
25. Singer G, Oldt R, III, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih IeM. 2003. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484-486.
26. Strathdee G, MacKean MJ, Illand M, Brown R. 1999. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18:2335-2341.
27. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, Birrer MJ. 1993. P53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 53:3103-3108.
28. Watson RH, Neville PJ, Roy WR, Jr, Hitchcock A, Campbell IG. 1998. Loss of heterozygosity on chromosomes 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis. Oncogene 17:207-212.
29. Williams GT, Farzaneh F. 2004. The use of gene function to identify the rate-limiting steps controlling cell fate. Cancer Immunol Immunother 53:160-165.
30. Williams GT, Hughes JP, Stoneman V, Anderson CL, McCarthy NJ, Mourtada-Maarabouni M, Pickard M, Hedge VL, Trayner I, Farzaneh F. 2006. Isolation of genes controlling apoptosis through their effects on cell survival. Gene Ther Mol Biol 10:255-262.
31. Wilson TR, Johnston PG, Longley DB. 2009. Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 9:307-319.
32. Yokoyama Y, Sato S, Fukushi Y, Sakamoto T, Futaqami M, Saito Y. 1999. Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynecol 25:387-394.